Understanding the intricate relationship between FND and PTSD requires a thorough examination of the disruptions prevalent in emotion processing and regulation. Individuals with both disorders often struggle with managing their emotional responses, which can lead to overwhelming feelings of anxiety, fear, or distress. This emotional dysregulation not only exacerbates symptoms but also complicates recovery, as individuals frequently find themselves unable to process experiences in a healthy manner. The implications of these emotional responses can thus set the stage for developing more integrated therapeutic approaches that address these foundational issues.

Interoceptive processing — the ability to perceive internal body signals — is another commonality observed between FND and PTSD. Research indicates that individuals with these conditions may possess an impaired ability to recognize and interpret physiological signals, potentially leading to a disconnect between their emotional experiences and bodily sensations. This fundamental disconnection might manifest as physical symptoms in FND, while in PTSD, it could reinforce the cycle of hyperarousal and numbing, further detaching individuals from their responses to stress and trauma. By addressing these interoceptive disruptions in therapy, clinicians could tailor interventions that bridge the divide between emotional awareness and physical sensations.

Dissociation, characterized by disruptions in the integration of consciousness, memory, and identity, is another critical feature shared by FND and PTSD. Many individuals may experience dissociative symptoms as a coping mechanism in response to overwhelming trauma or stress. When dissociation occurs, it can significantly impair one’s ability to engage with their environment and leads to further psychological distress. Understanding how dissociative mechanisms operate in both disorders could provide invaluable insights into more effective treatment modalities, emphasizing the need for therapeutic strategies that help patients ground themselves in their experiences.

Physiological stress responses also present a compelling area of research. Both FND and PTSD are associated with heightened stress reactivity, often manifesting in bodily symptoms such as tremors, paralysis, or unexplained sensations in FND, and intrusive memories and hyperarousal in PTSD. These overlapping physiological responses highlight a broader neurobiological underpinning that could be instrumental in designing targeted interventions. A unified approach to treatment could consider these physiological dimensions as key components of a holistic strategy, addressing both the symptoms and root causes inherent in these disorders.

The concept of fear-extinction learning offers yet another avenue for exploration in understanding these disorders. Both FND and PTSD can involve maladaptive fear responses, suggesting that individuals may struggle to form new associations in the presence of stressors. This could hinder their abilities to process past traumas or stressful experiences healthily. Bridging the gap between research on fear-extinction learning in PTSD and therapeutic practices for FND could facilitate the development of clinical strategies that rewire these associations, reinforcing adaptive coping mechanisms and emotional resilience.

As the research landscape evolves, the intersection of FND and PTSD invites a transdiagnostic mechanism-focused approach to treatment. By recognizing the psychological and biological overlaps between these disorders, healthcare professionals can harness evidence from established PTSD interventions to create innovative and effective strategies for FND. Such shifts in therapeutic paradigms could significantly enhance the potential for addressing symptoms of FND, particularly among individuals with emotion-regulation difficulties and complex symptom profiles that include histories of trauma.

Promising treatments, such as prolonged exposure therapy and the unified protocol for transdiagnostic treatment of emotional disorders, merit further investigation in the context of FND. These therapies, which have shown effectiveness in alleviating symptoms of PTSD, could be adapted to address similar dysfunctions in emotion regulation and physiological stress responses in FND patients. As this line of inquiry progresses, a wealth of existing therapeutic frameworks may be mobilized to create tailored interventions that align with the unique needs of individuals grappling with FND.

However, it is crucial to acknowledge that rigorous empirical validation is necessary to confirm the efficacy of transdiagnostic approaches within treatment settings. As clinical and neuroscientific insights converge, the landscape for understanding and addressing complex neuropsychiatric features in FND can be further refined. Establishing a robust evidence base not only enhances the credibility of these interventions but also fosters wider acceptance in clinical practice, ultimately benefiting patients navigating these challenging disorders.

In summary, the connections between FND and PTSD present an exciting frontier in psychological research and treatment. By illuminating shared areas of disruption and dysfunction, researchers and clinicians can collaborate to refine therapeutic interventions that cater to the unique challenges faced by individuals suffering from these debilitating conditions. Through sustained exploration and validation of novel treatment approaches, it is possible to pave the way for significant advancements in the care provided to those affected by FND, fostering hope and healing in their journeys toward recovery.

As the scientific community continues to unravel the complexities between these two disorders, the collaboration between research and clinical practice stands to transform the therapeutic landscape. Insights gleaned from ongoing studies will undoubtedly catalyze innovations that empower individuals with FND, offering them tools and strategies to reclaim their emotional well-being and navigate their experiences with newfound resilience.

Ultimately, the integration of research on PTSD into FND treatment not only holds promise for improved patient outcomes but also emphasizes the importance of adopting a multifaceted perspective in understanding the nature of these disorders. This transdiagnostic approach has the potential to bridge gaps, fostering targeted interventions that resonate with the intricate ways in which these conditions intertwine. As further studies elucidate the neurobiological and psychological commonalities between FND and PTSD, the healthcare community may be poised to revolutionize treatment options, helping countless individuals find a path to recovery.

Subject of Research: Connections between Functional Neurological Disorder and Posttraumatic Stress Disorder

Article Title: Insights from Posttraumatic Stress Disorder to Inform Treatment of Functional Neurological Disorder

Article References:

Putica, A., Agathos, J. & Felmingham, K. How insights from posttraumatic stress disorder can inform treatment of functional neurological disorder. Nat Rev Psychol 4, 654–668 (2025). https://doi.org/10.1038/s44159-025-00479-1

Image Credits: AI Generated

DOI:

Keywords: Neurobiology, Emotional Regulation, PTSD, FND, Therapeutics, Transdiagnostic Approaches

PTSD, a debilitating psychiatric condition triggered by exposure to traumatic events, manifests through symptoms such as intrusive memories, hyperarousal, and emotional numbing. Despite its prevalence and the profound impact on quality of life, the neurochemical mechanisms governing PTSD remain only partially understood. The endocannabinoid system—particularly the CB1 receptor, which is predominantly expressed in the central nervous system—has emerged as a candidate for influencing stress-related disorders due to its regulatory role in emotional processing and memory.

The investigative team employed PET imaging, a sophisticated neuroimaging technique allowing visualization and quantification of specific receptor populations in vivo, to measure CB1 receptor availability directly within pertinent brain regions of individuals diagnosed with PTSD. This modality involves the administration of radioligands that selectively bind to CB1 receptors, producing signals detectable by the PET scanner. By precisely quantifying these signals, researchers can infer receptor density and distribution patterns correlated with PTSD symptomatology.

Their analyses revealed a marked reduction in CB1 receptor availability across several limbic and cortical areas implicated in emotion regulation and fear extinction, including the amygdala, hippocampus, and prefrontal cortex. These findings suggest that alterations in endocannabinoid neurotransmission may contribute to the disturbed stress responses and maladaptive memory processing characteristic of PTSD. Notably, diminished CB1 receptor density correlates with severity of core PTSD symptoms, highlighting potential biomarkers for disease progression.

Moreover, the study elucidated that the decreased receptor availability is unlikely to be a mere epiphenomenon but rather reflects underlying neuropathological changes, possibly involving receptor internalization or downregulation secondary to chronic stress exposure. This distinction carries substantial weight for therapeutic strategies aimed at modulating the endocannabinoid system, emphasizing the need for interventions capable of restoring receptor function or expression.

Beyond its scientific contributions, the research holds significant translational promise. The current pharmacological treatments for PTSD, including selective serotonin reuptake inhibitors (SSRIs), display limited efficacy and often come with considerable side effects. Targeting CB1 receptors directly or indirectly could present a novel class of therapeutics with potentially greater specificity and improved tolerability. Preclinical models have demonstrated that enhancing endocannabinoid signaling can ameliorate anxiety and facilitate fear extinction, reinforcing the clinical relevance of these PET imaging findings.

The study also addresses the complexities inherent in measuring receptor availability, acknowledging potential confounding factors such as receptor affinity changes and ligand competition. By employing rigorous methodological controls and advanced radioligands with high specificity and affinity for CB1, the researchers minimized these limitations, thus conferring robustness to their conclusions. Additionally, longitudinal assessments could further delineate whether CB1 alterations precede PTSD manifestation or represent consequences of chronic illness.

Importantly, this research invites a reevaluation of the paradigm by which PTSD is conceptualized neurobiologically. The involvement of the endocannabinoid system situates the disorder within a broader context of neuroplasticity and homeostatic regulation, challenging prevailing monoaminergic-centric models. This integrative approach acknowledges the multifaceted neurochemical disturbances accompanying PTSD and underscores the value of multimodal imaging combined with molecular neuroscience.

Furthermore, the implications extend into personalized medicine. Stratifying PTSD patients based on CB1 receptor availability patterns might inform individualized treatment plans, enhancing therapeutic response rates while minimizing adverse effects. Biomarker-driven approaches anchored by PET imaging data could optimize clinical outcomes and reduce the trial-and-error nature of current pharmacotherapies.

The study’s findings also fuel ongoing debates regarding cannabis use and PTSD. Although exogenous cannabinoids interact with CB1 receptors, their therapeutic role remains controversial due to the complex psychoactive effects and potential for dependency. By delineating the endogenous receptor alterations intrinsic to PTSD, the research clarifies the biological substrate underlying these concerns and may guide safer, more effective cannabinoid-based treatments.

Critically, future research is poised to explore the dynamic interplay between CB1 receptor availability and other neurotransmitter systems, such as glutamatergic and GABAergic pathways, which collectively orchestrate emotional regulation and stress resilience. Multimodal imaging studies combining PET with functional MRI could yield richer mechanistic insights, potentially identifying critical circuit-level dysfunctions amenable to intervention.

Moreover, the development of next-generation radioligands with enhanced resolution and sensitivity will refine our understanding of CB1 receptor physiology in both healthy and pathological states. These technological advances promise to transform neuropsychiatric research paradigms, advancing from static receptor mapping to real-time monitoring of receptor trafficking and signaling.

In conclusion, the demonstration of decreased CB1 receptor availability in PTSD patients via PET imaging represents a landmark discovery with profound implications. This research adds a vital piece to the puzzle of PTSD neurobiology, emphasizing the endocannabinoid system’s central role while charting a course for novel, receptor-targeted therapies. As neuroscience continues to unravel the mysteries of trauma-related disorders, such insights will be indispensable in fostering hope for millions affected worldwide.

Subject of Research: Cannabinoid 1 receptor availability in posttraumatic stress disorder

Article Title: Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study

Article References:
Korem, N., Bassir Nia, A., Hillmer, A.T. et al. Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study. Transl Psychiatry 15, 310 (2025). https://doi.org/10.1038/s41398-025-03519-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03519-9

The research centers on the role of serotonin, a key neuromodulator involved in mood regulation, anxiety, and cognitive processing. While serotonin’s involvement in fear and anxiety has been extensively studied, its differential effects based on biological sex, particularly within specialized brain pathways, remain elusive. Using a sophisticated combination of pharmacological, optogenetic, molecular, and electrophysiological techniques in mouse models, the research team led by Ravenelle and colleagues explores how serotonergic modulation within the anterior dorsal bed nucleus of the stria terminalis (adBNST) influences fear memory formation, revealing striking sex-specific distinctions.

Fear conditioning, a widely used experimental paradigm, simulates traumatic experiences by associating a neutral auditory stimulus with an aversive event. This method enables precise examination of fear memory encoding, consolidation, and retrieval. The researchers began by pharmacologically increasing serotonin levels prior to auditory fear conditioning in both female and male mice. Remarkably, memory recall was enhanced in both sexes; however, females displayed a heightened sensitivity to the serotonergic manipulation, exhibiting more robust fear memory recall. This finding served as a pivotal first indicator that serotonin’s modulatory effects in fear circuits are not uniform across sexes.

Delving deeper, the team utilized optogenetics, an innovative technique allowing precise temporal and spatial control of neuronal activity using light-sensitive proteins. Specifically, raphe nucleus serotonin-releasing terminals projecting to the adBNST were selectively stimulated during the fear conditioning process. This targeted activation resulted in increased c-Fos expression, a marker of neuronal activity, within the adBNST and the central nucleus of the amygdala (CeA) — a hub critical for processing emotional responses. Importantly, these cellular activations translated into significantly enhanced fear memory recall, but critically, only in female mice.

Subsequent pharmacological interventions pinpointed the receptor subtype responsible for this effect: the 5-HT_2C receptor within the adBNST. Blockade of 5-HT_2C receptors abolished the serotonergic enhancement of fear memory in females, confirming that these receptors mediate the sex-specific modulation. This receptor-specific pathway offers tantalizing clues into the molecular substrates that confer vulnerability to excessive fear learning and PTSD-like phenotypes in females, suggesting a potential therapeutic target for sex-tailored PTSD interventions.

Electrophysiological recordings revealed another layer of complexity: high gamma oscillatory synchrony between the adBNST and CeA, occurring in the 90–140 Hz frequency range, was significantly enhanced during both fear learning and memory recall episodes in female mice exposed to serotonin stimulation. Gamma oscillations are widely implicated in cognitive processes, including attention, memory encoding, and information transfer between brain regions. This enhanced synchrony suggests that serotonin facilitates more coherent communication along the adBNST–CeA axis during fear processing in females, possibly underpinning the stronger fear memories observed.

Conversely, male mice did not exhibit comparable increases in gamma synchrony or fear memory enhancement following serotonergic or optogenetic manipulations, underscoring a fundamental sex difference in the neural dynamics supporting fear learning. This dichotomy aligns with epidemiological data indicating greater PTSD prevalence in women and suggests that sex-based differences in circuit-level serotonin function could drive divergent behavioral outcomes following trauma exposure.

The adBNST–CeA pathway emerges from this work as a critical neural circuit integrating serotonergic modulation and sex differences in fear processing. The bed nucleus of the stria terminalis (BNST) has long been implicated in sustained anxiety and stress responses, while the amygdala serves as a core node for fear learning and emotional evaluation. Their functional interplay, modulated by serotonin via 5-HT_2C receptors, appears to configure the neural landscape for sex-specific fear memory encoding, likely influenced by hormonal milieu and receptor expression patterns.

These insights into neurotransmitter systems and oscillatory dynamics reveal a novel dimension of how sex influences brain circuitry underlying trauma-related disorders. Most previous research has overlooked the dimension of sex in serotonin signaling within fear-related pathways, focusing instead on global serotonin levels or amygdala activity alone. The compelling demonstration that sex differences arise from fine-tuned serotonergic modulation within a discrete circuit connecting the raphe nuclei, adBNST, and CeA paves the way for more nuanced conceptual frameworks of PTSD pathophysiology.

Clinical implications of this work are profound. Current pharmacotherapies, including selective serotonin reuptake inhibitors (SSRIs), are prescribed for PTSD without differentiation by sex or circuit specificity. The findings presented by Ravenelle et al. argue for consideration of receptor subtype targeting, perhaps focusing on 5-HT_2C receptors within BNST-related networks, as an avenue to enhance treatment efficacy in women. Furthermore, understanding gamma oscillatory mechanisms offers potential for novel neuromodulation strategies, such as deep brain stimulation or transcranial magnetic stimulation tailored to synchronize pathological circuits.

Moreover, the study underscores the importance of including female subjects in preclinical neuroscience research, highlighting how sex differences at molecular, cellular, and systems levels can inform personalized medicine. The enhanced sensitivity of females to serotonergic modulation of fear circuits could reflect evolutionary adaptations in stress responsiveness, yet it simultaneously confers heightened vulnerability to PTSD, a paradox that warrants further investigation.

Future research directions could focus on dissecting how hormonal fluctuations across estrous cycles interact with serotonin signaling in the adBNST–CeA pathway to dynamically modulate fear learning. Additionally, translational studies investigating whether similar mechanisms operate in humans might utilize neuroimaging combined with pharmacological probes to validate the relevance of the 5-HT_2C receptor and gamma oscillations in sex-specific PTSD phenotypes.

In summary, Ravenelle and colleagues have elucidated a sex-dependent serotonergic mechanism in the neural circuitry of fear, revealing that female mice display enhanced fear memory formation via 5-HT_2C receptor activation in the adBNST and increased high gamma synchrony with the CeA. These findings not only advance fundamental understanding of sex differences in fear learning but also open promising avenues for the development of sex-sensitive PTSD therapies. As the burden of trauma-related disorders continues to rise globally, such mechanistic insights offer a beacon of hope for more effective, personalized clinical interventions.

Subject of Research: Sex differences in serotonergic modulation of fear learning circuits in mice with implications for PTSD.

Article Title: Serotonergic modulation of the BNST–CeA pathway reveals sex differences in fear learning.

Article References:
Ravenelle, R., Lee, J., Fernandes-Henriques, C. et al. Serotonergic modulation of the BNST–CeA pathway reveals sex differences in fear learning. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02025-x

Image Credits: AI Generated